BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-160@catalystbrief.girapphe.com
DTSTAMP:20261119T001600Z
LAST-MODIFIED:20261119T001600Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Readout: Takeda — Zasocitinib [May 2027]
DESCRIPTION:Phase 3 primary completion: A Study of Zasocitinib in Adults Wi
 th Psoriatic Arthritis Who Have Not Taken Biologic Medicines.\nSource: htt
 ps://clinicaltrials.gov/study/NCT06671483\nhttps://catalystbrief.girapphe.
 com/e/160?lang=en\nNot investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/160?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
